Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
N/A
There is no consensus on the treatment of Impulse Control Disorder (ICD) in...
Status
Not Yet Recruiting
Location
Service de Neurologie et Centre d'Investigation Clinique CHRU de Besançon,
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
PHASE2
There is no consensus on the treatment of Impulse Control Disorder (ICD) in...